Collegium Pharmaceutical, Inc. (NASDAQ: COLL – Get a rating) received an average “Buy” recommendation from the seven research companies that cover the business, Marketbeat reports. One equity research analyst gave the stock a hold rating, four gave the company a buy rating and one issued a strong buy rating for the company. The 12-month average target price among analysts who have rated the stock over the past year is $30.60.
Several research analysts recently commented on the title. Piper Sandler raised her price target on shares of Collegium Pharmaceutical from $36.00 to $42.00 and gave the stock an “overweight” rating in a Tuesday, Feb. 22 research note. Needham & Company LLC raised its price target on Collegium Pharmaceutical shares from $28.00 to $34.00 and gave the company a “buy” rating in a Tuesday, February 15 research report. TheStreet upgraded shares of Collegium Pharmaceutical from a “c+” rating to a “b-” rating in a Thursday, March 3 research report. Cantor Fitzgerald moved shares of Collegium Pharmaceutical from a “neutral” rating to an “overweight” rating and raised his target price for the company from $18.00 to $26.00 in a Tuesday 15 research report. February. Ultimately, Zacks Investment Research moved shares of Collegium Pharmaceutical from a “hold” rating to a “strong-buy” rating and set a target price of $22.00 on the stock in a research report on Thursday, March 3.
In other news, EVP Scott Dreyer sold 10,559 shares of the company in a transaction dated Friday, February 18. The shares were sold at an average price of $21.61, for a total value of $228,179.99. The transaction was disclosed in a legal filing with the SEC, accessible via this link. 5.18% of the shares are currently held by insiders of the company.
Hedge funds have recently increased or reduced their holdings in the stock. Harel Insurance Investments & Financial Services Ltd. acquired a new stake in Collegium Pharmaceutical in Q3 worth approximately $28,000. Denali Advisors LLC acquired a new stake in Collegium Pharmaceutical during Q4 valued at approximately $32,000. Geneos Wealth Management Inc. acquired a new stake in Collegium Pharmaceutical during Q3 valued at approximately $43,000. Point72 Hong Kong Ltd acquired a new stake in Collegium Pharmaceutical during Q3 valued at approximately $44,000. Finally, the Royal Bank of Canada increased its stake in Collegium Pharmaceutical by 344.3% during the second quarter. Royal Bank of Canada now owns 3,110 shares of the specialty pharmaceutical company valued at $74,000 after acquiring an additional 2,410 shares during the period.
COLL stock opened at $19.33 on Friday. The company has a market capitalization of $645.24 million, a PE ratio of 11.44, a P/E/G ratio of 0.18 and a beta of 0.99. Collegium Pharmaceutical has a 12-month low of $17.07 and a 12-month high of $25.80. The company’s 50-day moving average is $18.81 and its 200-day moving average is $19.29. The company has a debt ratio of 0.99, a current ratio of 1.13 and a quick ratio of 1.07.
About Collegium Pharmaceutical (Get a rating)
Collegium Pharmaceutical, Inc operates as a pharmaceutical company. The company engages in the development and planning for commercialization of next-generation abuse-deterrent products for the treatment of patients with chronic pain and other diseases. Its products include Xtampza ER, Nucynta ER and Nucynta IR.
This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]
Should you invest $1,000 in Collegium Pharmaceutical right now?
Before you consider Collegium Pharmaceutical, you’ll want to hear this.
MarketBeat tracks Wall Street’s top-rated, top-performing research analysts daily and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes hold…and Collegium Pharmaceutical didn’t make the list.
Although Collegium Pharmaceutical currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
See the 5 actions here